ClinicalTrials.gg
Not yet recruitingNCT06739213Updated Dec 18, 2024

A Phase II Study of SYHA1813 for Recurrent or Progressive High-Grade Meningioma

A Phase 2 interventional study of SYHA1813 and Investigator's Choice Treatment in Recurrent or Progressive High Grade Meningioma, sponsored by Shanghai Runshi Pharmaceutical Technology Co., Ltd. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-18.

Primary conditionnone(registry's first term: Recurrence)No conditionIs this wrong?Recurrence describes something many studies share rather than a condition a study is about. The study names no condition we can place it under, so it is not compared with other studies by condition.

Sponsored by Shanghai Runshi Pharmaceutical Technology Co., Ltd · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a randomized, controlled, open-label, multicenter, Phase II clinical study designed to evaluate the efficacy and safety of SYHA1813 compared to investigators' choice in participants with recurrent or progressive high-grade meningioma.

Read the detailed description

A total of 56 participants with recurrent or progressive high-grade meningioma who are not eligible for local therapy will be enrolled. Participants will be randomized 1:1 to receive either SYHA1813 (experimental group) or investigators' choice (control group). The primary endpoint is the 6-month progression-free survival (PFS) rate assessed by investigators using the Response Assessment in Neuro-Oncology Working Group( RANO criteria) for meningioma.

02

Conditions studied

  • Recurrent or Progressive High Grade Meningioma

Browse trials for

03

In context

Lead sponsor

Shanghai Runshi Pharmaceutical Technology Co., Ltd is the lead sponsor of 9 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged >= 18 years;
  2. confirmed WHO grade II/III meningioma (WHO CNS 5th)
  3. There is at least one in the baseline period (RANO-meningioma);
  4. ≥60;
  5. The expected survival time is >=3 months;
  6. The organ function level and related laboratory indicators must meet requirements (no blood transfusion within 2 weeks):
  7. Female participants of must have a negative the blood pregnancy test results of within 7 days prior to randomization and agree to use reliable and effective during the study treatment period and for at least 3 months after the last study treatment (or as required by the drug's instructions). Male participants with partners of childbearing potential must agree to use reliable and effective contraception during the study treatment period and for at least 3 months after the last study treatment (or as required by the drug's instructions).

Exclusion criteria

Exclusion Criteria:

  1. Patients who are known or suspected to be allergic to the test drug or its components;
  2. Meets one of the following conditions: patients with brainstem involvement; patients with severe brain herniation or at risk of brain herniation; patients with extracranial during the screening period.
  3. A history of any other malignant tumors within 3 years (except for effectively controlled skin basal cell carcinoma, cutaneous squamous cell carcinoma, superficial bladder cancer or cured carcinoma in situ);
  4. Use of at an equivalent dose exceeding 5mg of dexamethasone within 7 days prior to randomization.
  5. The toxicity of previous anti-tumor treatments has not recovered to Grade1(including brain edema after radiotherapy), with the exception of hair loss, uncomplicated laboratory abnormalities that do not require medical intervention, and other adverse reactions deemed by the investigator not to affect the safety of the study medication.;
  6. Use of a strong inhibitor within 14 days prior to randomization or ongoing use of such inhibitors.
  7. Current use of warfarin or other oral anticoagulants (except for low-dose anticoagulants used to maintain central venous access or prevent deep vein thrombosis).
  8. Inability to undergo contrast-enhanced MRI
  9. Patients with evidence of bleeding tendency or medical history within 2 moths
  10. Urine protein ≥ 2+, and 24-hour urine protein quantitative ≥ 1.0g/24h;
  11. (HIV) antibody positive; active (anti-HCV antibody positive and HCV RNA test positive); active (HBV DNA test for HBsAg is positive and HBV DNA is equal to or higher than 2×10\^3 IU/ml));
  12. The subject has poorly healed wounds, ulcers or fractures;
  13. Presence of a severe chronic or active infection (including tuberculosis and other infections).requiring intravenous antibiotic, antifungal, or antiviral treatment within 14 days prior to randomization
  14. Other severe systemic diseases, including but not limited to uncontrolled diabetes, kidney disease requiring dialysis, severe liver disease ( class B or C), acute pancreatitis, etc.
  15. Subjects with cardiovascular and cerebrovascular diseases.
  16. Underwent major organ surgery within 28 days prior to randomization (excluding procedures).
  17. Received chemotherapy (including temozolomide), targeted therapy, immunotherapy, hormone therapy, or other antitumor treatments within 28 days prior to randomization; or used any NMPA-approved traditional Chinese medicine or patent Chinese medicine with anticancer activity within 14 days prior to randomization (regardless of cancer type).
  18. Subjects with dysphagia or known drug absorption disorders.
  19. Pregnant or lactating women.
  20. Presence of other conditions that may interfere with the participant's ability to comply with the study procedures or that may not allow the participant to derive the maximum benefit from the study, or that may affect the study outcomes, such as a history of psychiatric disorders, drug or substance abuse, or any other clinically significant disease or condition.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    Experimental group

    SYHA1813

    Drug: SYHA1813

  • Active comparator
    Control group

    Investigator's Choice Treatment

    Drug: Investigator's Choice Treatment

Interventions

  • The starting dose of SYHA1813 is 20mg QD

  • DrugInvestigator's Choice Treatment

    Investigator's Choice Treatment

06

What researchers measure

Primary outcomes

  1. the Progression-free survival (PFS) at 6-month(PFS-6)as evaluated by investigator (RANO-meningioma)

    Time frame: Up to approximately 3years

Secondary outcomes

  1. Progression-free survival (PFS) as evaluated by INV (RANO-meningioma)

    Time frame: Up to approximately 3years

  2. Objective response rate (ORR) as evaluated by INV (RANO-meningioma)

    Time frame: Up to approximately 3years

  3. Disease control rate (DCR) as evaluated by INV (RANO-meningioma)

    Time frame: Up to approximately 3years

  4. Overall survival (OS)

    Time frame: Up to approximately 3years

  5. Frequency and severity of TEAE and SAE

    Time frame: Up to approximately 3years

  6. Maximum Plasma Concentration of SYHA1813 (Cmax)

    Time frame: Up to approximately 3years

  7. The scores of the 30-item European Organisation for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)

    The EOTCT QLQ-C30 is designed to measure the health-related quality of life (HRQoL) across different cancer types and stages. It has demonstrated good evidence of content validity for assessing functional health, symptom burden, and health-related quality of life in patients with localized to advanced cancer. The questionnaire comprises 30 items that are combined to form five functional scales (physical, role, cognitive, emotional, and social), three symptom scales (fatigue, pain, and nausea/vomiting), and six single items (appetite loss, diarrhea, constipation, dyspnea, insomnia, and financial difficulties), as well as a global health status/quality of life scale. The global health status scale is scored on a 7-point scale, while the other items are scored on a 4-point scale. Higher scores indicate a higher level of response.

    Time frame: Up to approximately 3years

  8. The scores of the 20-item EORTC QLQ for Brain Neoplasm (-BN20)

    The EORTC QLQ-BN20 is a 20-item questionnaire specifically designed for assessing the health-related quality of life (HRQOL) and symptoms in patients with brain cancer, including both primary brain tumors and brain metastases. Within the EORTC framework, there is a distinction between functional scales (e.g., "Emotional Functioning") and symptom scales (e.g., "Pain"). High scores on functional scales indicate better functioning, while high scores on symptom scales indicate a greater symptom burden.

    Time frame: Up to approximately 3years

  9. The score of The Neurologic Assessment in Neuro-Oncology (NANO) scale

    The NANO scale evaluates 9 major domains of neurologic function that are most relevant to patients with supratentorial, infratentorial, and brainstem tumors, including gait, strength, upper extremity ataxia, sensation, visual fields, facial strength, language, level of consciousness, and behavior. As designed, the gait domain includes assessment of lower extremity ataxia. Each domain is subdivided into 3 or 4 levels of function with scores based on discrete quantifiable measures. Thus, levels of function for each domain range from 0 to 2 or 0 to 3. A score of 0 indicates normal function, while the highest score indicates the most severe level of deficit for that domain. Levels of function are distinguished by significant and measurable differences in order to avoid misinterpretation of subtle or nonspecific changes.

    Time frame: Up to approximately 3years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2025; primary completion for Jan 2027, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2024
First posted
Dec 18, 2024
StartEst.
Jan 31, 2025
Primary completionEst.
Jan 31, 2027
CompletionEst.
Jan 13, 2028
Last update
Dec 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06739213
Lead sponsor
Shanghai Runshi Pharmaceutical Technology Co., Ltd
Responsible party
Sponsor
First posted
Dec 18, 2024
Start date
Jan 31, 2025 (estimated)
Primary completion
Jan 31, 2027 (estimated)
Completion
Jan 13, 2028 (estimated)
Last update
Dec 18, 2024

Study contacts

Clinical Trials Information Group officer
Contact
ctr-contact@cspc.cn
86-0311-69085587

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SYHA1813

Start the discussion